newsio aggregates and links to original sources. We do not own the original images or content. If you believe content infringes on intellectual property rights, contact us — it will be removed at first notice.
biotech/news//The Economic Times
Vikas Khemani-backed Q-Line Biotech's IPO opened on Wednesday, aiming to raise up to Rs 214.48 crore on NSE Emerge.
Q-Line Biotech's IPO was subscribed over 2 times on its first day.
KEY POINTS
The company is commanding a Grey Market Premium (GMP) of 42% over the issue price.
During the Covid-19 pandemic, Q-Line began manufacturing RT-PCR and RNA extraction kits.
Q-Line Biotech reported a profit after tax of Rs 38.69 crore for the nine months ending December 2025.
Synopsis
Vikas Khemani-backed Q-Line Biotech's IPO opened on Wednesday, aiming to raise up to Rs 214.48 crore on NSE Emerge. The company, operating in the in-vitro diagnostics and healthcare solutions segment, saw strong subscription on its first day. Proceeds will be used for working capital, debt repayment, and general corporate purposes.
Listen to this article in summarized format
Loading...
×
Vikas Khemani-backed Q-Line Biotech opened its IPO on Wednesday, looking to raise up to Rs 214.48 crore through the NSE Emerge platform. The IPO consists of 62.53 lakh equity shares with a price band of Rs 326-343 per share. The company is commanding one of the strongest GMPs in recent past at 42% over the issue price.
The issue has been subscribed over 2 times on the first day, led by institutional investors and retail investors. The QIB portion was booked over 3 times, while the retail quota was subscribed just over 2 times.
Q-Line Biotech operates in the in-vitro diagnostics (IVD) and healthcare solutions segment, manufacturing diagnostic reagents, rapid testing kits, molecular diagnostics products, pathology equipment and related consumables used by hospitals, laboratories and healthcare institutions.
At the upper end of the price band, the company is targeting a total issue size of Rs 214.48 crore. The issue will close on May 25. Investors can bid for a minimum lot size of 400 shares.
The allocation structure includes up to 17.81 lakh shares reserved for anchor investors and up to 11.88 lakh shares for qualified institutional buyers. Retail investors will have access to at least 20.79 lakh shares, while non-institutional investors will get not less than 8.91 lakh shares.
Live Events
The company plans to utilise IPO proceeds primarily toward working capital requirements, repayment of certain borrowings and general corporate purposes.
Founded in 2013, Q-Line Biotech develops and supplies diagnostic products across segments including clinical chemistry, haematology, immunodiagnostics and molecular diagnostics. Its product portfolio also includes point-of-care devices and rapid diagnostic kits.
The company manufactures reagents and diagnostic consumables while also importing and distributing pathology equipment and related healthcare products.
During the Covid-19 pandemic, the company expanded into manufacturing Covid testing products including RT-PCR kits, RNA extraction kits and viral transport medium kits through internal research and third-party technical collaborations.
Q-Line Biotech said it has built its brand presence over the past 12 years through research and development capabilities, manufacturing infrastructure and quality assurance systems.
On the financial front, the company reported revenue of Rs 313.78 crore in FY25 compared with EBITDA of Rs 71.32 crore and profit after tax of Rs 28.13 crore. For the nine months ended December 2025, revenue stood at Rs 232.42 crore, while EBITDA came in at Rs 64.22 crore and PAT at Rs 38.69 crore.
HEM Securities and Share India Capital Services are the book-running lead managers to the issue, while Purva Sharegistry is acting as registrar.
(You can now subscribe to our ETMarkets WhatsApp channel)
(What's moving Sensex and Nifty Track latest market news, stock tips, Budget 2025, Share Market on Budget 2025 and expert advice, on ETMarkets. Also, ETMarkets.com is now on Telegram. For fastest news alerts on financial markets, investment strategies and stocks alerts, subscribe to our Telegram feeds .)
Subscribe to ET Prime and read the Economic Times ePaper Online.and Sensex Today.
Top Trending Stocks: SBI Share Price, Axis Bank Share Price, HDFC Bank Share Price, Infosys Share Price, Wipro Share Price, NTPC Share Price
...moreless
(You can now subscribe to our ETMarkets WhatsApp channel)
(What's moving Sensex and Nifty Track latest market news, stock tips, Budget 2025, Share Market on Budget 2025 and expert advice, on ETMarkets. Also, ETMarkets.com is now on Telegram. For fastest news alerts on financial markets, investment strategies and stocks alerts, subscribe to our Telegram feeds .)
Subscribe to ET Prime and read the Economic Times ePaper Online.and Sensex Today.
Top Trending Stocks: SBI Share Price, Axis Bank Share Price, HDFC Bank Share Price, Infosys Share Price, Wipro Share Price, NTPC Share Price
...moreless
NSE gets EDs, paycheck draws past parallels
An unusual skill shortage that’s stalling govt’s PNG push
Is Air India the cocktail turning bitter for Tatas?
3 years on, India rebuilds aircraft lessors’ trust that Go First broke
Falling prices, Gulf risks: A spice king’s growth recipe falters
Stock Radar: Down 27% from highs! Patanjali Foods stock showing signs of bottoming out – time to buy?
1
2
3